Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

d supply of clinical material until transfer of manufacturing.

TB-403 (Anti-PIGF) has completed an initial Phase I clinical trial and recently received approval to enter a Phase Ib dose escalation trial. This Phase Ib trial will be conducted in patients with advanced cancer and is due to commence shortly in Denmark.

TB-403 has the potential to be a major advance in the treatment of cancer. It is a humanized monoclonal antibody that blocks the formation of the new blood vessels that are needed by solid tumours to support their growth. TB-403 has the potential to minimize both the growth and spread of cancer cells.

Professor Désiré Collen, CEO and Chairman of ThromboGenics, said: "TB-403 has generated a great deal of interest from the pharmaceutical community. Therefore, we are delighted that we have signed this major licensing agreement with Roche, given their expertise and success in bringing novel anti-cancer agents to the market. This deal represents a significant milestone in ThromboGenics' development as a company. It also reflects TB-403's potential as a promising treatment for cancer, and is a testament to the hard work and high quality science on which ThromboGenics' business is based. The funding from this deal also gives us the financial resources to continue to build our strong pipeline. We look forward to working with Roche, and to the successful development of this unique anti-cancer agent."

Svein Mathisen, CEO of BioInvent, commented on the deal: "We believe that TB-403 has great potential for the treatment of cancer, with its unique mode of action targeting PlGF, and are delighted that Roche has recognised this potential. This agreement demonstrates our ability to identify innovative projects and to realize the clinical potential of a therapeutic antibody. We look forward to seeing the product progress further through clinical development and towards market."

Dan Zabrowski, Global Head of Pharma Partnering, Roche adde
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 While ... in health services research for a relatively long ... in interest regarding the use of these ‘big ... conditions. , By combining today’s powerful computer technology ... digital era, ‘big data’ holds significant promise for ...
(Date:7/30/2014)... With the accelerated aging of ... expenditure as well as the improved medical care ... reagent industry has been developing quickly, especially in ... Chinese in vitro diagnostics market size reached RMB22.98 ... vitro diagnostic reagents. , Read complete report ...
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 ... State-of-the-art facility and complementary therapies brings comprehensive cancer ... foot, state-of-the-art Yuma Regional Cancer Center has officially ... 2012, the program includes services such as open, ... massage therapy, American Cancer Society Resource Center, hematology, ...
(Date:7/30/2014)...   Epic Sciences, Inc. ("Epic"), a private ... personalize and advance the treatment and management of cancer, ... as chairman of Epic,s board of directors. Mr. ... (formerly Invitrogen). Mr. Lucier joins Epic,s board of directors ... cell analysis platform with special focus on the development ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... announces that a new market research report is ... Oxide: 2010 World Market Outlook And Forecast ... report analyzes worldwide markets for Propylene oxide, including ... provides the most complete and current analytical account ...
... (Nasdaq: MYL ) today announced its financial results for ... its financial guidance for 2011.   Financial Results ... ended December 31, 2010 compared to $0.33 for the same prior ... of $1.61 for the year ended December 31, 2010 compared to ...
... in German . , They have been used ... now they are making rapid inroads in high performance applications: ... phones and digital cameras. The automotive industry, for instance, has ... using them in driver assistance systems from parking aids ...
Cached Biology Technology:Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 16Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 17Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 18UV-transparent coating for image sensors 2
(Date:7/30/2014)... NexID Biometrics , a leading ... for the biometric authentication industry, has recently joined ... authentication with standards for strong authentication. According to ... to join FIDO Alliance stems from NexID,s mission ... We believe the FIDO Alliance is a key ...
(Date:7/30/2014)... colors, nature had already perfected the process think ... example. Now scientists are tapping into those secrets to ... plastics. Their paper on using structure or the ... to produce color appears in the ACS journal ... and colleagues point out that currently, plastic manufacturers add ...
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2F1000Research brings static research figures to life 2
... studies reveal that voting decisions are more associated ... a politician,s appearance than to positive ones, says ... of Technology (Caltech), Scripps College, Princeton University, and ... particularly true when voters have little or no ...
... beware. Chances are your male partner is on your ... even when you have kept to the straight and ... constant vigilance, women may be better than men at ... in Richmond and colleagues gave 203 young heterosexual couples ...
... sustainability expert Deane Evans will provide an introduction to the basics of ... seminar, open to the public, at NJIT. The talk, set ... a review of the status of the NJ schools, construction program. ... Evans, a registered architect, is executive director ...
Cached Biology News:Caltech-led researchers find negative cues from appearance alone matter for real elections 2Caltech-led researchers find negative cues from appearance alone matter for real elections 3Caltech-led researchers find negative cues from appearance alone matter for real elections 4Men are better at detecting infidelities 2
... Polymerase is ideal for high-fidelity amplification ... such as cloning and mutagenesis. ... proprietary enzyme preparation containing recombinant DNA ... (3'Cut Site5' exonuclease) activity. Platinum ...
... precision beveling of micropipette tips ... unique abrasive plate drive system ... control of the beveling process. ... rapidly and produces consistent tip ...
... mM sodium phosphate buffer, pH 6.5. Cathepsin ... a major lysosomal aspartyl protease in mammalian ... Overexpression of cathepsin D in human breast ... relapse and metastasis. Cathepsin D degrades extracellular ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: